DADC
ALNY icon

D.A. Davidson & Co’s Alnylam Pharmaceuticals ALNY Stock Holding History

D.A. Davidson & Co’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-3,098
Closed -$593K – 1386
2023
Q4 		$593K Sell
3,098
-192
-6% -$32.7K 0.01% 888
2023
Q3 		$583K Buy
3,290
+57
+2% +$10.9K 0.01% 851
2023
Q2 		$614K Buy
3,233
+20
+0.6% +$3.96K 0.01% 860
2023
Q1 		$644K Sell
3,213
-36
-1% -$7.57K 0.01% 822
2022
Q4 		$772K Buy
3,249
+273
+9% +$58.2K 0.01% 706
2022
Q3 		$596K Sell
2,976
-1,105
-27% -$211K 0.01% 758
2022
Q2 		$595K Buy
4,081
+100
+3% +$14.2K 0.01% 766
2022
Q1 		$650K Sell
3,981
-248
-6% -$37.8K 0.01% 788
2021
Q4 		$717K Buy
4,229
+187
+5% +$34.8K 0.01% 755
2021
Q3 		$763K Buy
4,042
+171
+4% +$32.1K 0.01% 710
2021
Q2 		$656K Buy
3,871
+246
+7% +$36K 0.01% 752
2021
Q1 		$512K Buy
3,625
+763
+27% +$115K 0.01% 798
2020
Q4 		$372K Buy
2,862
+632
+28% +$84.4K 0.01% 792
2020
Q3 		$325K Buy
2,230
+221
+11% +$31.4K 0.01% 751
2020
Q2 		$298K Buy
2,009
+78
+4% +$10.5K 0.01% 752
2020
Q1 		$210K Buy
+1,931
New +$223K ﹤0.01% 854
2017
Q3 		– Sell
-150
Closed -$11K – 1106
2017
Q2 		$11K Buy
150
+10
+7% +$639 ﹤0.01% 2001
2017
Q1 		$7K Hold
140
– – ﹤0.01% 2103
2016
Q4 		$5K Hold
140
– – ﹤0.01% 2250
2016
Q3 		$9K Buy
140
+25
+22% +$1.76K ﹤0.01% 2063
2016
Q2 		$6K Buy
115
+47
+69% +$2.96K ﹤0.01% 2068
2016
Q1 		$4K Buy
68
+36
+113% +$2.39K ﹤0.01% 2070
2015
Q4 		$3K Buy
+32
New +$2.97K ﹤0.01% 2076

Other funds holding ALNY

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

D.A. Davidson & Co's ALNY Position: Q1 2024 in Review

D.A. Davidson & Co sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2024, closing a stake of 3,098 shares — an estimated $593K sold.

D.A. Davidson & Co first reported a position in ALNY in Q4 2015 and held it in 23 quarters. The position peaked at $772K in Q4 2022. 499 funds tracked by Wall St. Rank hold ALNY as of Q1 2024.

  • D.A. Davidson & Co reported no remaining Alnylam Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • D.A. Davidson & Co sold 3,098 Alnylam Pharmaceuticals shares in Q1 2024, an estimated $593K.
  • D.A. Davidson & Co first reported a position in Alnylam Pharmaceuticals in Q4 2015 and held it in 23 quarters.
  • D.A. Davidson & Co's Alnylam Pharmaceuticals position peaked at $772K in Q4 2022.
  • 499 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2024.

Based on D.A. Davidson & Co's 13F filing for Q1 2024, filed 13 May 2024.